VIRX: Koefisien rega marang pendapatan Viracta
Viracta Therapeutics develops cutting-edge oncology drugs whose global expansion is secured by robust patent protection. The brand is valued for its precision method of combating lymphomas through the activation of viral genes. Currently, the company is developing a line of agents against the Epstein-Barr virus based on the "kick and kill" principle. The volatility of the P/S ratio clearly demonstrates the market valuation, while the indicator reflects the current dynamics.
Viracta Therapeutics (VIRX) - rincian metrik lan laporan keuangan
- rega saiki lan proyeksi nilai saham:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Viracta Therapeutics|VIRX - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal viracta.com|VIRX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Viracta|VIRX - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Viracta Therapeutics|Rasio likuiditas perantara viracta.com
- informasi bathi lan kelipatan valuasi:
VIRX - Bathi resik|Penghasilan resik sing dikarepake Viracta Therapeutics|VIRX - Pangali P/E|Rasio prakiraan rega marang bathi viracta.com|VIRX - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Viracta|VIRX - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Viracta Therapeutics|VIRX - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan viracta.com|VIRX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Viracta Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:VIRX Viracta Therapeutics Inc.
The P/S multiple compares a business's market value to its annual sales volume, making it possible to determine the premium paid per unit of revenue. Analyzing the price/sales multiple of Viracta Therapeutics (VIRX) helps identify entry points when assets are undervalued, as the company's capitalization is based on the development of breakthrough epigenetic drugs for targeted gene management in the therapy of viral forms of cancer.
Karo sapa Viracta Therapeutics saingan
Rasio rega marang pendapatan ONC (beigene.com)|Multiplikator P/S HALO (Halozyme)|Koefisien rega marang pendapatan Revolution Medicines Inc (RVMD)|AAPG - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CGON (CG Oncology Therapeutics)|URGN: Multiplikator P/S|bicara.com (BCAX) - Multiplikator P/S|PSNL (Personalis) - Multiplikator P/S|Kapitalisasi marang pendapatan Erasca Inc (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Kapitalisasi marang volume dodolan YMAB|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Multiplikator P/S Candel Therapeutics Inc. CADL|ARAY: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|CTOR: Kapitalisasi marang volume dodolan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|TARA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S FATE|WHWK - Rega marang dodolan|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|Rasio kapitalisasi pasar marang pendapatan CSBR|XBiotech USA - Multiplikator P/S|CVM - Multiplikator P/S|OS Therapies (OSTX) - Rasio rega marang pendapatan|Rasio rega marang dodolan RADX (radiopharmtheranostics.com)|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Rega marang dodolan Adlai Nortye Limited ANL|Kapitalisasi marang pendapatan VERU (Veru Inc.)|Multiplikator P/S tempesttx.com (TPST)|Xilio Therapeutics - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan RENB (Renovaro Biosciences)|Mural Bio - Multiplikator P/S|Koefisien rega marang pendapatan Kairos Pharma Ltd KAPA|OKUR: Multiplikator P/S|Kapitalisasi marang pendapatan CytoMed Therapeutics Limited|Rasio rega marang pendapatan Curis Inc.|Apollomics Corp (APLM) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan THAR (Tharimmune Corp)|Rasio rega marang pendapatan ADVB (advanbiomed.com)|Multiplikator P/S GNPX (Genprex, Inc.)|Koefisien rega marang pendapatan Calidi Biotherapeutics Inc. (CLDI)|SBFM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan XBIO (Xenetic Biosciences)|SLRX (Salarius) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan PPBT|AONC (American Oncology Network Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan beigene.com (BGNE)|Multiplikator P/S CKPT|Multiplikator P/S elevationoncology.com (ELEV)|Rasio rega marang pendapatan iCAD ICAD|IKNA: Rasio kapitalisasi marang pendapatan|Notable Labs, Ltd. - Multiplikator P/S|morphosys.com (MOR) - Kapitalisasi marang pendapatan|NAYA: Multiplikator P/S|Rega marang dodolan Ascentage Pharma Group International (AAPGV)
